Human Trials Set for Experimental HIV Vaccine
An experimental HIV vaccine protected animals from dozens of strains of HIV. And a human trial of the vaccine is expected to begin in the second half of 2019, according to U.S. researchers.
The vaccine targets a vulnerable site on HIV -- the virus that causes AIDS -- and triggered antibody production in mice, guinea pigs and monkeys, according to researchers with the U.S. National Institute of Allergy and Infectious Diseases (NIAID).
Read more: https://www.drugs.com/news/human-trials-set-experimental-hiv-vaccine-74828.html
The vaccine targets a vulnerable site on HIV -- the virus that causes AIDS -- and triggered antibody production in mice, guinea pigs and monkeys, according to researchers with the U.S. National Institute of Allergy and Infectious Diseases (NIAID).
Read more: https://www.drugs.com/news/human-trials-set-experimental-hiv-vaccine-74828.html